Most traditional vaccines use a dead or weakened ... This allows them to answer many questions about the drugs. If an HIV treatment doesn't work for you, or you find your medication regimen ...

£5 allows us to reach millions of people globally with accurate and reliable resources about HIV prevention and treatment ... herbal or traditional medicines, and recreational drugs. Older age and ...

Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. Researchers ...

in place of traditional three-drug regimens. Usually these studies have involved simplification strategies in which treatment-naive patients with a stable and undetectable plasma HIV RNA of <50 ...

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

Identifying HIV cases is the first step in addressing clusters, and quickly learning one’s status allows people to rapidly seek both treatment and prevention. Unlike traditional laboratory-based ...

These results support doravirine / islatravir as an alternative to traditional multi-drug regimens, offering a simplified option for people with HIV who have no history of treatment failure or ...

As new data and new antiretroviral drugs and formulations become available, recommendations for HIV treatment ... providing adherence support through traditional methods such as pill boxes ...

Ultimately, Ambati's research underscores the critical need for new perspectives in combating Alzheimer's, moving beyond traditional drug targets. By repurposing established HIV medications ...

But these drugs are often expensive, and those with HIV that live in developing countries often can’t access them. They are also life-long treatments since antiretrovirals don’t fully eradicate the ...

with 90 per cent of the 30 million people living with HIV on a treatment regimen that includes this drug. Currently, resistance to DTG is low, at around 4 per cent, but for groups of patients who ...